These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37313428)

  • 1. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
    Xiong X; Song Q; Jing M; Yan W
    Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.
    Wu Z; Guo L; Wan L; Xu K; Luo L; Wen Z
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11891-11905. PubMed ID: 37410140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.
    Wei Y; Lan C; Yang C; Liao X; Zhou X; Huang X; Xie H; Zhu G; Peng T
    Sci Rep; 2023 Sep; 13(1):14519. PubMed ID: 37666920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
    Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
    Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
    Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
    Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
    He Q; Yang J; Jin Y
    Front Immunol; 2022; 13():869993. PubMed ID: 35493518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
    Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
    Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
    Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
    Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
    Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.
    Zhao C; Zhang Z; Tao J
    Curr Oncol; 2022 Sep; 29(10):6992-7011. PubMed ID: 36290827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
    Chen J; Gao G; Zhang Y; Dai P; Huang Y
    BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.